SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer

SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer is a phase 2, interventional study registered as NCT05576480 by Ruijin Hospital, with a registry enrolment figure of 55 participants, started 2023-02-06 and due to reach its primary completion in 2025-10. Interventions recorded: Short-course radiotherapy; Penpulimab; CAPEOX; TME surgery. Conditions listed: Rectal Cancer; Locally Advanced. Primary outcome: Pathological complete remission rate (pCR). Colorectal eligibility wording from the registry: "* Patients with pathologically confirmed rectal adenocarcinoma, assessed by MRI as mid-low rectal cancer (the lower border of the tumor is less than 10cm from the anal verge), clinical stage II-III (cT1-2N1-2M0 or T3-4N0-2M0) according to the 8th Edition of AJCC Cancer Staging Manual". Sites: China. No results are recorded here; the registry entry is the source.